EP3522929A2 - Nouvelles compositions de furazidine et leurs procédés de préparation - Google Patents

Nouvelles compositions de furazidine et leurs procédés de préparation

Info

Publication number
EP3522929A2
EP3522929A2 EP17797439.1A EP17797439A EP3522929A2 EP 3522929 A2 EP3522929 A2 EP 3522929A2 EP 17797439 A EP17797439 A EP 17797439A EP 3522929 A2 EP3522929 A2 EP 3522929A2
Authority
EP
European Patent Office
Prior art keywords
weight
furazidin
composition according
agent
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP17797439.1A
Other languages
German (de)
English (en)
Inventor
Piotr Paduszynski
Katarzyna CZESCIK
Piotr Potaczek
Malgorzata HAN-MAREK
Tomasz HAN
Stanislaw Han
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centrum Badawczo-Rozwojowe Novasome Spolka Z Ograniczona Odpowiedzialnoscia
Przedsiebiorstwo Produkcji Farmaceutycznej Hasco-Lek SA
Original Assignee
Centrum Badawczo-Rozwojowe Novasome Spolka Z Ograniczona Odpowiedzialnoscia
Przedsiebiorstwo Produkcji Farmaceutycznej Hasco-Lek SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PL419047A external-priority patent/PL234271B1/pl
Priority claimed from PL421505A external-priority patent/PL234395B1/pl
Application filed by Centrum Badawczo-Rozwojowe Novasome Spolka Z Ograniczona Odpowiedzialnoscia, Przedsiebiorstwo Produkcji Farmaceutycznej Hasco-Lek SA filed Critical Centrum Badawczo-Rozwojowe Novasome Spolka Z Ograniczona Odpowiedzialnoscia
Priority to EP19209609.7A priority Critical patent/EP3643325B1/fr
Publication of EP3522929A2 publication Critical patent/EP3522929A2/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Definitions

  • the object of the present invention is an oral pharmaceutical composition comprising furazidin, a method of using it, and a method of manufacturing it.
  • Furazidin (Furaginum) is a derivative of nitrofuran, broad- spectrum chemotherapeutic agent. It acts against both Gram-positive and Gram-negative bacteria. It demonstrates bacteriostatic effect inter alia on Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus faecal is, Salmonella, Shigella, Proteus, Klebsiella, Escherichia, Enterobacter. Furazidin is used for treatment and prophylaxis of acute and chronic urinary tract infections.
  • Furazidin is administered in oral form - in the form of tablets.
  • Tablets comprise corn starch, sucrose, colloidal silicon dioxide and stearic acid as excipients.
  • the dosage form of a tablet is not very suitable for some groups of patients who have problems with swallowing e.g. children or elderly persons.
  • furazidin was described by Paberza, M. et al.: practiceSome aspects of the excretion of furagin with the urine of rabbits", Farmatsiya (Moscow, Russian Federation) (1980.06.30), 29(3), pp. 66-7, and by Hillers, S. et al.: dueNew chemical therapeutic preparation for the treatment of intestinal infections: furazidine (F-35)", Med. Nauka-Praktike (Riga: Akad. Nauk S.S.R.) Sbornik (1957), pp. 63-5.
  • Capsules comprising furazidin is sold at the market under commercial name Furamag.
  • the filling of the capsules comprises furazidin, lactose monohydrate, maize starch and purified talc.
  • An oral pharmaceutical composition comprising furazidin according to the invention is in the form of suspension.
  • the composition comprises from 0,5% by weight to 20% by weight of furazidin.
  • the composition comprises at least one polyhydric alcohol or/and at least one sugar or their mixture in an amount from 5 to 80% by weight and water in an amount to 80% by weight.
  • the composition comprises at least one substance chosen from the group consisting of sorbitol, glycerol, mannitol, sucrose, glucose or/and fructose.
  • composition according comprises at least one suspending agent .
  • the composition comprises at least one suspending agent chosen from the group consisting of arabic gum, carbomer, xanthan gum, modified or/and unmodified starch, mixture of microcrystalline cellulose and croscarmellose sodium and/or their mixtures.
  • the composition comprises a suspending agent in an amount from 0,1% by weight to 10% by weight.
  • the composition comprises at least one flavoring agent or/and preservative.
  • preservatives benzoic acid; salts of benzoic acid e.g. sodium benzoate; esters of p-hydroxybenzoic acid e.g. methyl p- hydroxybenzoate, ethyl p-hydroxybenzoate, propyl p- hydroxybenzoate; sorbic acid; salts of sorbic acid e.g. potassium sorbate.
  • the composition comprises at least one buffering mixture.
  • buffering mixtures are used: citrate buffer, acetate buffer, phosphate buffer, oxalate buffer, citrate-phosphate buffer.
  • the composition has pH between 2 and 9
  • a method of using the composition according to the invention consists in that the composition is administered to a mammal, including a human, in an amount providing a daily intake of furazidin from 25 to 600 mg.
  • Daily dosage may be administered once, or may be divided into smaller dosages and may be taken several times a day, preferably from 2 to 4 times a day.
  • a dosage for children shall be calculated using a ratio 5-7 mg/kg of child's body weight per day.
  • a method of manufacturing the composition according to the invention consists in that a phase I is obtained in such a way, that the suspending agent is dispersed in a part of purified water, then polyhydric alcohol or/and sugar, furazidin and possibly flavoring agents are added, the whole is homogenized, then a phase II is obtained in such a way that preservatives or/and the mixture of buffering mixtures is dissolved in the remaining part of the purified water, then the phase II is added to the phase one, the whole is homogenized and de-aerated.
  • a method of manufacturing the composition according to the invention consists in that the suspending agent is dispersed in purified water, then polyhydric alcohol or/and sugar, and possibly flavoring substances, preservatives and buffering mixtures are dissolved, the whole is homogenized, and then furazidin is added, the whole is mixed and homogenized until a homogeneous suspension is obtained, and then it is de-aerated.
  • polyhydric alcohol or/and at least one sugar or their mixture in an amount from 5 to 80% by weight and water in an amount to 80% by weight are used.
  • the polyhydric alcohol or/and sugar is chosen from the group consisting of sorbitol, glycerol, mannitol, sucrose, glucose or/and fructose.
  • the suspending agent is chosen from the group consisting of arabic gum, carbomer, xanthan gum, modified or/and unmodified starch, mixture of microcrystalline cellulose and croscarmellose sodium and/or their mixtures.
  • the amount of suspending agent is from 0,1% by weight to 10% by weight.
  • At least one flavoring agent or/and preservative and at least one buffer may be used.
  • preservative are used: benzoic acid; salts of benzoic acid e.g. sodium benzoate; esters of p-hydroxybenzoic acid e.g. methyl p-hydroxybenzoate, ethyl p-hydroxybenzoate, propyl p-hydroxybenzoate; sorbic acid; salts of sorbic acid e.g. potassium sorbate.
  • buffering mixtures are used: citrate buffer, acetate buffer, phosphate buffer, oxalate buffer, citrate-phosphate buffer.
  • the composition obtained by the method according to the invention has pH between 2 and 9.
  • a pharmaceutical composition comprising furazidin according to the invention is in the form of powder or/and granules or/and coated granules.
  • the composition according to the invention may be directly administered to a patient. It may be used for preparation of oral suspension or/and a filling of hard capsule. It may be used for preparation of pellets or/and coated pellets or/and minitablets or/and coated minitablets, and they may constitute a filling of hard capsules.
  • the composition according to the invention may be suspended in a dispersion phase what enables filling of soft capsule or/and hard capsule.
  • the composition has non-modified release characteristics.
  • modified release shall be understood as prolonged release, delayed release, pulsatile release or accelerated release.
  • the composition comprises from 0.5% by weight to 95% by weight of furazidin.
  • the composition comprises at least one compound having binding or/and coating properties in an amount from 0.1% by weight to 30 % by weight.
  • the compound having binding or/and coating properties is chosen from the group consisting of saccharides, polyhydric alcohols, polymers of acrylic acid derivatives, polymers of methacrylic acid derivatives, polymers of vinyl alcohol derivatives, chemically modified cellulose derivatives, polyvinylpyrrolidones and/or polyethylene oxides.
  • Saccharides used in the composition are e.g. sucrose or/and dextrins
  • polyhydric alcohols are e.g. sorbitol, mannitol
  • chemically modified cellulose derivatives are e.g. hydroxypropyl cellulose, hydroxypropyl methylcellulose, cellulose phthalates or/and cellulose acetate.
  • Polyvinylpyrrolidones used in the compositions are e.g. povidone K15/17 or/and povidone K25
  • polyethylene oxides are e.g. PEG 400 or/and PEG 6000.
  • the composition comprises at least one compound having emulsifying properties in an amount from 0.1% by weight to 45% by weight chosen from the group consisting of phospholipids, polyoxyethylene sorbitan derivatives, fatty acids and/or fatty alcohols.
  • Phospholipids used in the compositions are soya lecithin or/and sunflower lecithin, and sorbitan derivatives are e.g. sorbitan sesquioleate.
  • Fatty acids used in the composition are e.g. oleic acid, fatty alcohols are e.g. oleic alcohol.
  • the composition comprises at least one compound chosen from the group of surfactants (e.g. sodium lauryl sulfate) in an amount from 0.1% by weight to 15% by weight.
  • surfactants e.g. sodium lauryl sulfate
  • the composition comprises at least one bulking agent in an amount from 5% by weight to 99% by weight.
  • Bulking agents used are e.g. starch, gelatinized starch, microcrystalline cellulose, lactose, glucose, mannitol, sorbitol, talc, dextrins or/and their mixture.
  • the composition comprises at least one lubricant in an amount from 0.1% by weight to 10% by weight.
  • Lubricants used are e.g. stearic acid, magnesium stearate, talc or/and their mixture.
  • the composition comprises at least one substance chosen from the group consisting of sweetening agents, flavoring agents and buffering agents in an amount from 0.01% by weight to 25% by weight.
  • the composition may comprise just one of these agents or any of their mixtures.
  • Sweetening agents used are e.g. sucrose, acesulfame K, sodium saccharin or/and sucralose.
  • Flavoring agents comprised in the composition are e.g. orange, cherry, lemon or/and banana flavor
  • buffering agents are e.g. sodium dihydrogen phosphate, sodium hydrogen phosphate, citric acid or/and sodium citrate.
  • the object of the present invention is also a method of manufacturing the composition as defined above which consists in that a water or/and organic solution of the substance having binding properties is prepared, then furazidin is mixed with the substance having emulsifying properties and/or with the bulking agent, then the mixture of furazidin with the substance having emulsifying properties and/or with the bulking agent is granulated with addition of the binding substance solution, after granulation the obtained granules are calibrated and dried, and then they are mixed with a bulking agent and/or a lubricant and/or a surfactant and/or a sweetening agent and/or a flavouring agent and/or a buffering agent.
  • the composition obtained by this method is in the form of granules.
  • the water or/and the organic solution of the substance having binding and/or coating properties used in the method has concentration from 5% by weight to 90% by weight.
  • Granules directly after drying or after drying and calibration, and before mixing with other substances is coated with coating agents.
  • the object of the present invention is also a method of manufacturing the composition as defined above in the form of a powder.
  • the method consists in that furazidin is mixed with a bulking agent or/and a binding agent or/and an emulsifying agent or/and a surfactant or/and a lubricant or/and a sweetening agent or/and a flavoring agent or/and a buffering agent.
  • Quantitative-qualitative composition of the formulation is depicted below.
  • Phase I Xanthan gum was dispersed in the part of purified water. Sorbitol and Glycerol were added. Phase II: In a separate vessel Sodium benzoate and Potassium sorbate were dissolved in the remaining part of purified water. Furazidin and flavor were added to Phase I. Homogenization was performed at speed from 100 to 6 000 rpm not less than for 5 min. Phase II was added. Homogenization was performed, and then the whole was stirred until de-aeration.
  • Quantitative-qualitative composition of the formulation is depicted below.
  • Phase I Xanthan gum was dispersed in the part of purified water. Sorbitol and Glycerol were added. Phase II: In a separate vessel Sodium benzoate and Potassium sorbate were dissolved in the remaining part of purified water. Furazidin and flavor were added to Phase I. Homogenization was performed at speed from 100 to 6 000 rpm not less than for 5 min. Phase II was added. Homogenization was performed, and then the whole was stirred until de-aeration.
  • Quantitative-qualitative composition of the formulation is depicted below.
  • Phase I Xanthan gum was dispersed in the part of purified water. Sorbitol and Glycerol were added. Phase II: In a separate vessel Sodium benzoate and Potassium sorbate were dissolved in the remaining part of purified water. Furazidin and flavor were added to Phase I. Homogenization was performed at speed from 100 to 6 000 rpm not less than for 5 min. Phase II was added. Homogenization was performed, and then the whole was stirred until de-aeration.
  • Quantitative-qualitative composition of the formulation is depicted below.
  • Phase I Carbomer was dispersed in the part of purified water. NaOH was added. Stirring was performed for n.m.n 10 min. Sucrose and Glycerol were added.
  • Phase II In a separate vessel Sodium benzoate and Potassium sorbate were dissolved in the remaining part of purified water. Furazidin and flavor were added to Phase I. Homogenization was performed at speed from 100 to 6 000 rpm not less than for 5 min. Phase II was added. Homogenization was performed. The whole was stirred until de- aeration.
  • Quantitative-qualitative composition of the formulation is depicted below.
  • Phase I Carbomer was dispersed in the part of purified water. NaOH was added. Stirring was performed for not less than 10 min. Sucrose was added. Phase II: In a separate vessel Sodium benzoate and Potassium sorbate were dissolved in the remaining part of purified water. Furazidin and flavor were added to Phase I. Homogenization was performed at speed from 100 to 6 000 rpm not less than for 5 min. Phase II was added. Homogenization was performed. The whole was stirred until de- aeration.
  • Quantitative-qualitative composition of the formulation is depicted below.
  • Phase I Xanthan gum was dispersed in the part of purified water. Sorbitol and Glycerol were added.
  • Phase II In a separate vessel Citric acid, Sodium citrate, Sodium benzoate and Potassium sorbate were dissolved in the remaining part of purified water. Furazidin and flavor were added to Phase I. Homogenization was performed at speed from 100 to 6 000 rpm not less than for 5 min. Phase II was added. Homogenization was performed. The whole was stirred until de-aeration.
  • Quantitative-qualitative composition of the formulation is depicted below.
  • Quantitative-qualitative composition of the formulation is depicted below.
  • Quantitative-qualitative composition of the formulation is depicted below. No. Name of the ingredient % wt/wt
  • Quantitative-qualitative composition of the formulation is depicted below.
  • the ingredients 7 to 11 were added and mixed until smooth, but but not less than 3 min. It is possible to mix each ingredient in a separate cycle of mixing or/and all ingredients together.
  • the ingredient 5 was added. The whole was mixed until smooth, but not less than 3 min.
  • the mass obtained was filled into sachets.
  • the product obtained may be administered directly to a patient or/and used for preparation of a suspension directly before administration.
  • Quantitative-qualitative composition of the formulation is depicted below.
  • a water solution of the ingredients 3 and 11 was prepared.
  • the ingredients 1 , 2 and 7 were placed. The whole was mixed until smooth, however not shorter than 3 minutes. It is possible to mix all ingredients together or separately.
  • the mixture was granulated with use of the water solution of the ingredient 3 and 11.
  • the granules were calibrated.
  • the granules were dried to achieve dryness from 0.5 to 25%.
  • the ingredients 6, 8, 9 and 10 were added to the obtained granules.
  • the whole was mixed until smooth, but not less than 3 min. It is possible to mix each ingredient in a separate cycle of mixing or/and all ingredients together.
  • the ingredient 4 and 5 was added. The whole was mixed until smooth, but not less than 3 min.
  • the mass obtained was filled into sachets.
  • the product obtained may be administered directly to a patient or/and used for preparation of a suspension directly before administration.
  • SUM 100 Description of technological process: A dispersion of the ingredients 3 and 11 was prepared. In the apparatus for wet granulation the ingredients 1 , 2 and part of portion of the ingredient 7 were placed. It is possible to use the ingredient 7 in proportion from 0 to 100%. Granulation was performed with use of the solution of the ingredients 3 and 11. Obtained granules were calibrated in case of need, and then dried to achieve dryness from 0.5 to 25%. After drying the granules obtained were calibrated in case of need. The rest of the portion of the ingredient 7 was added to the obtained granules, (if 100% of the portion of the ingredient 7 is used for granulation, this step shall be omitted). Next ingredients 6, 9 and 10 were added to the mixture.
  • Example 14 The whole was mixed until smooth, but not less than 3 min. It is possible to mix each ingredient in a separate cycle of mixing or/and all ingredients together. The ingredient 4 and 5 was added. The whole was mixed until smooth, but not less than 3 min. It is possible to mix each ingredient in a separate cycle of mixing or/and all ingredients together. The product obtained may be administered directly to a patient or/and used for preparation of a suspension directly before administration.
  • Example 14
  • a water dispersion of the ingredient 7 was prepared.
  • the water solution of the ingredient 7 shall have the concentration from 50 to 200 % wt/wt, and it is possible to use maximal ratio of the solvent : ingredient 3 as 1 :2.
  • Non-used part of the portion of the ingredient 7 will be used in the next step of the process.
  • the ingredients 1 and 2 were placed. It is possible to use the ingredient 8 in proportion from 0 to 100%.
  • Granulation was performed with use of the solution of the ingredient 7. Obtained granules were calibrated in case of need. They were dried to achieve dryness from 0.5 to 25%.
  • a water solution of the ingredient 3 was prepared. Dried granules were fluid coated with the solution of the ingredient 3.
  • the remaining portions of the ingredients 7 and 8 were added, and then 8 and 9. The whole was mixed until smooth, but not less than 3 min. It is possible to mix each ingredient in a separate cycle of mixing or/and all ingredients together.
  • the ingredients 4 and 5 were added. It is possible to mix each ingredient in a separate cycle of mixing or/and all ingredients together.
  • the product obtained may be administered directly to a patient or/and used for preparation of a suspension directly before administration.
  • a water solution of the ingredient 3 was prepared.
  • the ingredients 1 and 2 were placed.
  • the ingredients 1 and 2 were mixed.
  • Granulation was performed in a fluid bed with use of the solution of the ingredient 3.
  • the ingredients 4 and 5 were added to the obtained granules.
  • the whole was mixed until smooth, but not less than 3 min. It is possible to mix each ingredient in a separate cycle of mixing or/and all ingredients together.
  • the ingredient 4 and 5 was added.
  • the whole was mixed until smooth, but not less than 3 min.
  • the product obtained is intended for obtaining pellets or minitablets, that may be coated and constitute a filling for hard capsules or/and may be suspended in a dispersion phase what enables filling of soft capsule or/and hard capsule.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Cette invention concerne une composition de furazidine sous forme de suspension. L'invention concerne également un procédé de préparation de ladite composition comprenant une phase I obtenue par dispersion de l'agent de mise en suspension dans une partie de l'eau purifiée, puis ajout d'un alcool polyhydrique et/ou d'un sucre, de la furazidine et éventuellement d'agents aromatisants, avant homogénéisation, et une phase II obtenue par dissolution de conservateurs et/ou du mélange de tamponnage dans le reste de l'eau purifiée, après quoi la phase II est ajoutée à la phase I. La composition de furazidine peut être préparée sous forme de poudre et/ou de granulés et/ou de granulés enrobés. Un procédé de fabrication de ladite composition comprenant la préparation d'une solution aqueuse et/ou organique de la substance ayant des propriétés de liaison, l'incorporation par mélange de la furazidine à la substance ayant des propriétés émulsifiantes et/ou à l'agent d'expansion, puis la granulation du mélange est en outre décrit. Les granulés obtenus sont calibrés et séchés, et éventuellement mélangés à d'autres excipients.
EP17797439.1A 2016-10-10 2017-10-06 Nouvelles compositions de furazidine et leurs procédés de préparation Pending EP3522929A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP19209609.7A EP3643325B1 (fr) 2016-10-10 2017-10-06 Composition comprenant de la furazidine et son procédé de fabrication

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PL419047A PL234271B1 (pl) 2016-10-10 2016-10-10 Doustna kompozycja farmaceutyczna zawierająca furazydynę w postaci zawiesiny oraz sposoby jej wytwarzania
PL421505A PL234395B1 (pl) 2017-05-08 2017-05-08 Doustna kompozycja farmaceutyczna zawierająca furazydynę i sposób jej wytwarzania
PCT/IB2017/056199 WO2018069804A2 (fr) 2016-10-10 2017-10-06 Nouvelles compositions de furazidine et leurs procédés de préparation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP19209609.7A Division EP3643325B1 (fr) 2016-10-10 2017-10-06 Composition comprenant de la furazidine et son procédé de fabrication

Publications (1)

Publication Number Publication Date
EP3522929A2 true EP3522929A2 (fr) 2019-08-14

Family

ID=60302423

Family Applications (2)

Application Number Title Priority Date Filing Date
EP19209609.7A Active EP3643325B1 (fr) 2016-10-10 2017-10-06 Composition comprenant de la furazidine et son procédé de fabrication
EP17797439.1A Pending EP3522929A2 (fr) 2016-10-10 2017-10-06 Nouvelles compositions de furazidine et leurs procédés de préparation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP19209609.7A Active EP3643325B1 (fr) 2016-10-10 2017-10-06 Composition comprenant de la furazidine et son procédé de fabrication

Country Status (3)

Country Link
EP (2) EP3643325B1 (fr)
RU (1) RU2019110218A (fr)
WO (1) WO2018069804A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL236891B1 (pl) * 2017-06-21 2021-02-22 Aflofarm Farm Polska Spolka Z Ograniczona Odpowiedzialnoscia Płynna forma podawania furazydyny oraz sposób jej otrzymywania
EP4032530A1 (fr) * 2021-01-25 2022-07-27 Adamed Pharma S.A. Composition de furazidine à libération prolongée

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4500516A (en) * 1982-10-22 1985-02-19 Institut Organicheskogo Sinteza Akademii Nauk Latviiskoi Ssr Antibacterial pharmaceutical composition
RU2103997C1 (ru) * 1995-04-19 1998-02-10 Акционерное общество закрытого типа "Гекта" Лекарственное средство для лечения заболеваний животных микробной этиологии, способ лечения желудочно-кишечных заболеваний животных микробной этиологии и способы лечения гинекологических заболеваний коров микробной этиологии
RU2626671C2 (ru) * 2015-08-05 2017-07-31 Федеральное государственное бюджетное образовательное учреждение высшего образования "Нижегородская государственная медицинская академия" Министерства здравоохранения Российской Федерации (ФГБОУ ВО НижГМА Минздрава России) Лекарственное средство для лечения поражений мягких тканей организма

Also Published As

Publication number Publication date
WO2018069804A2 (fr) 2018-04-19
EP3643325A1 (fr) 2020-04-29
RU2019110218A3 (fr) 2021-03-30
EP3643325B1 (fr) 2024-04-10
WO2018069804A3 (fr) 2018-07-19
RU2019110218A (ru) 2020-11-13

Similar Documents

Publication Publication Date Title
BRPI0608853B1 (pt) composições farmacêuticas e processo para a fabricação de microgrânulos de rifaximina gastrorresistentes
US20130071476A1 (en) Rapid Melt Controlled Release Taste-Masked Compositions
JP6796132B2 (ja) 液体剤形中の薬学的活性化合物放出性多層微小粒子
BRPI0818118B1 (pt) Composição farmacêutica na forma de uma suspensão aquosa estabilizada de carisbamato e seu processo de formação
KR102631488B1 (ko) 디아민 유도체를 함유하는 구강내 붕괴정
NO335273B1 (no) Blanding omfattende cefuroxim axetil i partikulær form samt farmasøytisk blanding for oral administrering
WO2015034678A2 (fr) Corticostéroïde contenant des compositions de comprimés se désintégrant par voie orale pour œsophagite à éonisophiles
CA2977168C (fr) Granules gastro-resistants contenant un inhibiteur de la pompe a protons
EP3522929A2 (fr) Nouvelles compositions de furazidine et leurs procédés de préparation
EP2538923A2 (fr) Poudre à goût masqué pour compositions en suspension de méthylprednisolone
KR101383430B1 (ko) 새로운 조합의 구강내 속붕해 필름형성 조성물 및 ｐｄｅ５ 저해제가 함유된 구강내 속붕해 필름제제
RU2240784C1 (ru) Лекарственное средство на основе арбидола
TWI644688B (zh) 含有崩解性粒子組成物之口腔內崩解錠劑之製造方法
EA029586B1 (ru) Фармацевтическая композиция для лечения вич-инфекций
US20040191326A1 (en) Taste-masking vehicle for coated oxazolidinone particles
WO2020039264A2 (fr) Suspension pharmaceutique chimiothérapeutique pour forme galénique orale
AU2010351281B2 (en) Ciprofloxacin dry syrup composition
KR20180091572A (ko) 경구투여용 대장하제조성물
ES2731598T3 (es) Formulación pediátrica que comprende ácido biliar
US20240091367A1 (en) Orally disintegrating palatable formulations of drotaverine and method of preparation thereof
JP6150564B2 (ja) 口腔内速崩壊性錠剤
WO2024028263A1 (fr) Formulation de gépotidacine
TW202313072A (zh) 檸檬酸鐵之兒科調配物
TW201609193A (zh) 含有碳酸鹽之口腔內崩解錠劑用組成物及口腔內崩解錠劑
EP3675832A1 (fr) Formes posologiques à auto-dispersion rapide de déférasirox

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190502

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20220817